See the DrugPatentWatch profile for cosentyx

Based on the information available, there is some evidence to suggest that higher doses of Cosentyx (secukinumab) may be needed for obese patients. A study published in the Journal of Dermatological Treatment found that obese patients with psoriasis required higher doses of biologic therapies, including Cosentyx, to achieve optimal clinical responses [1].

The study authors suggest that the higher doses may be necessary due to the increased volume of distribution and clearance of the drug in obese patients. However, they note that further research is needed to confirm these findings and to establish the most effective dosing regimens for obese patients.

Additionally, DrugPatentWatch.com reports that there are currently no patents specifically related to the use of higher doses of Cosentyx in obese patients [2]. This suggests that there may be opportunities for further research and development in this area.

In summary, while there is some evidence to suggest that higher doses of Cosentyx may be needed for obese patients, more research is needed to confirm these findings and to establish the most effective dosing regimens.

Sources:
[1] <https://www.tandfonline.com/doi/full/10.1080/09546634.2020.1861825>
[2] <https://www.drugpatentwatch.com/drugs/cosentyx>